Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses
Charles River Laboratories has announced its agreement to acquire Frontage's Bioanalysis and DMPK (Drug Metabolism and Pharmacokinetics) businesses. This acquisition is expected to expand Charles River's capabilities in drug discovery and development services.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.